Immediate Treatment for Ventricular Tachycardia with Pulse

Hemodynamic Assessment

The American Heart Association recommends assessing hemodynamic stability by evaluating for adverse signs such as hypotension, chest pain, acute heart failure, altered mental status, and signs of shock in patients with ventricular tachycardia with pulse 1, 2
Hypotension is defined as a systolic blood pressure ≤90 mmHg in the context of ventricular tachycardia with pulse 2
Chest pain suggesting ongoing ischemia is a critical sign to assess in patients with ventricular tachycardia with pulse 3
Acute heart failure, characterized by pulmonary edema or dyspnea, is an adverse sign in ventricular tachycardia with pulse 1
Altered mental status is an indicator of inadequate cerebral perfusion in ventricular tachycardia with pulse 1
Signs of shock, including decreased urine output and cool extremities, are critical to identify in ventricular tachycardia with pulse 1

The American College of Cardiology recommends performing synchronized DC cardioversion immediately at escalating energy levels (100J, 200J, 360J) in hemodynamically unstable ventricular tachycardia with pulse 1, 2
Sedation should be provided before cardioversion if the patient is conscious but unstable 3, 2
Resuscitation equipment should be immediately available during cardioversion for ventricular tachycardia with pulse 5
Cardioversion should not be delayed to establish IV access or administer medications in hemodynamically unstable ventricular tachycardia with pulse 6

The European Society of Cardiology recommends amiodarone as the preferred antiarrhythmic for hemodynamically stable ventricular tachycardia, particularly in patients with structural heart disease or heart failure 3, 4
Amiodarone should be administered with a loading dose of 150 mg IV over 10 minutes, followed by a maintenance infusion of 1.0 mg/min for 6 hours, then 0.5 mg/min 3, 4
Amiodarone should be combined with IV beta-blockers for optimal efficacy in stable ventricular tachycardia with pulse 3, 4
Procainamide is an alternative first-line therapy, demonstrating the greatest efficacy among medical options for stable monomorphic ventricular tachycardia, with a loading infusion of 20-30 mg/min up to a maximum 10-17 mg/kg 3
Lidocaine is a second-line alternative, particularly useful when ventricular tachycardia is thought to be ischemia-related, with an initial bolus of 1.0-1.5 mg/kg IV (maximum 100 mg) 2, 4

The American Heart Association recommends administering magnesium 8 mmol (2 grams) IV bolus immediately for torsades de pointes (polymorphic ventricular tachycardia with long QT), especially if hypomagnesemia is suspected 3, 4
IV beta-blockers are the single most effective therapy for polymorphic ventricular tachycardia storm, and should be combined with amiodarone as first-line therapy 3

Calcium channel blockers (verapamil, diltiazem) should be avoided entirely in ventricular tachycardia patients, especially those with myocardial dysfunction, as they can precipitate ventricular fibrillation or profound hypotension 4
Adenosine should not be used for unstable or irregular/polymorphic wide-complex tachycardias, as it may cause degeneration to ventricular fibrillation 1
Class IC antiarrhythmics (flecainide, propafenone) should be avoided in patients with prior myocardial infarction or structural heart disease 3

IV drugs should always be administered with a 20 mL saline bolus to aid delivery to central circulation 2, 4
Electrolyte abnormalities (potassium >4.0 mEq/L, magnesium >2.0 mg/dL) should be corrected before and during antiarrhythmic therapy 3, 4
Patients should be monitored continuously for hypotension, bradycardia, and AV block during antiarrhythmic administration 4
Cardioversion equipment should be immediately available when administering any antiarrhythmic drug 5